GenSci accuses Osteotech of implant monopoly control
This article was originally published in Clinica
Executive Summary
GenSci Regeneration Sciences is taking its rival Osteotech to court claiming that its position in human tissue processing has permitted the company to leverage anti-competitive control in the osteogenic bone implant market.